$BIOCQ
Biocept Inc

2019 Q3 Form 10-Q Financial Statement

#000156459019043276 Filed on November 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q4 2018 Q3
Revenue $1.529M $859.5K $761.6K
YoY Change 100.8% -13.64% -31.48%
Cost Of Revenue $2.833M $2.435M $2.482M
YoY Change 14.14% 3.19% -0.21%
Gross Profit -$1.303M -$1.576M -$1.720M
YoY Change -24.23% 15.47% 25.06%
Gross Profit Margin -85.24% -183.33% -225.89%
Selling, General & Admin $3.163M $3.073M $3.198M
YoY Change -1.1% -6.67% -8.91%
% of Gross Profit
Research & Development $1.164M $1.289M $1.090M
YoY Change 6.77% 41.83% 27.2%
% of Gross Profit
Depreciation & Amortization $240.2K $220.0K $223.2K
YoY Change 7.62% 15.79% 39.89%
% of Gross Profit
Operating Expenses $4.326M $4.362M $4.288M
YoY Change 0.9% 3.82% -1.82%
Operating Profit -$5.630M -$5.938M -$6.008M
YoY Change -6.3% 6.68% 4.61%
Interest Expense $62.03K -$80.00K $63.76K
YoY Change -2.72% -20.0% -170.85%
% of Operating Profit
Other Income/Expense, Net -$62.03K $10.00K -$39.80K
YoY Change 55.85% -47.26%
Pretax Income -$5.692M -$6.010M -$6.048M
YoY Change -5.89% 6.18% 3.94%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.692M -$6.014M -$6.048M
YoY Change -5.89% 6.14% 3.89%
Net Earnings / Revenue -372.19% -699.72% -794.1%
Basic Earnings Per Share -$2.47 -$1.43 -$2.42
Diluted Earnings Per Share -$2.47 -$1.43 -$2.42
COMMON SHARES
Basic Shares Outstanding 2.302M 4.209M 2.767M
Diluted Shares Outstanding 2.302M 4.209M 2.760M

Balance Sheet

Concept 2019 Q3 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.540M $3.420M $8.960M
YoY Change -27.01% 59.07% 52.38%
Cash & Equivalents $6.539M $3.423M $8.956M
Short-Term Investments
Other Short-Term Assets $500.0K $430.0K $640.0K
YoY Change -21.88% 2.38% 56.1%
Inventory $687.2K $587.2K $580.0K
Prepaid Expenses
Receivables $2.862M $1.574M $1.480M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $10.59M $6.011M $11.65M
YoY Change -9.14% 41.26% 42.07%
LONG-TERM ASSETS
Property, Plant & Equipment $1.325M $2.739M $2.900M
YoY Change -54.3% -12.3% -0.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.936M $2.739M $2.902M
YoY Change 35.62% -12.3% -0.63%
TOTAL ASSETS
Total Short-Term Assets $10.59M $6.011M $11.65M
Total Long-Term Assets $3.936M $2.739M $2.902M
Total Assets $14.52M $8.750M $14.55M
YoY Change -0.21% 18.59% 30.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.834M $2.040M $1.790M
YoY Change 2.46% 60.61% 12.58%
Accrued Expenses $1.847M $1.928M $1.950M
YoY Change -5.28% 10.05% -10.14%
Deferred Revenue
YoY Change
Short-Term Debt $130.0K $0.00 $120.0K
YoY Change 8.33% -100.0% 0.0%
Long-Term Debt Due $780.0K $640.0K $570.0K
YoY Change 36.84% -59.49% -70.77%
Total Short-Term Liabilities $5.783M $4.610M $4.440M
YoY Change 30.25% -1.08% -23.97%
LONG-TERM LIABILITIES
Long-Term Debt $1.030M $990.0K $1.020M
YoY Change 0.98% -13.91% 7.37%
Other Long-Term Liabilities $0.00 $110.0K $160.0K
YoY Change -100.0% -59.26% -48.39%
Total Long-Term Liabilities $1.032M $1.098M $1.174M
YoY Change -12.1% -22.75% -6.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.783M $4.610M $4.440M
Total Long-Term Liabilities $1.032M $1.098M $1.174M
Total Liabilities $6.815M $5.708M $5.610M
YoY Change 21.49% -6.17% -20.87%
SHAREHOLDERS EQUITY
Retained Earnings -$240.0M -$220.5M
YoY Change 12.91%
Common Stock $247.7M $223.5M
YoY Change 13.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.705M $3.043M $8.938M
YoY Change
Total Liabilities & Shareholders Equity $14.52M $8.750M $14.55M
YoY Change -0.2% 18.59% 30.85%

Cashflow Statement

Concept 2019 Q3 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$5.692M -$6.014M -$6.048M
YoY Change -5.89% 6.14% 3.89%
Depreciation, Depletion And Amortization $240.2K $220.0K $223.2K
YoY Change 7.62% 15.79% 39.89%
Cash From Operating Activities -$5.610M -$5.420M -$5.460M
YoY Change 2.75% -5.74% 10.3%
INVESTING ACTIVITIES
Capital Expenditures -$210.0K $0.00 -$80.00K
YoY Change 162.5% -100.0% -84.91%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$210.0K $0.00 -$80.00K
YoY Change 162.5% -100.0% -84.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.500M
YoY Change 13.64%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -230.0K -110.0K 11.91M
YoY Change -101.93% -104.64% 782.22%
NET CHANGE
Cash From Operating Activities -5.610M -5.420M -5.460M
Cash From Investing Activities -210.0K 0.000 -80.00K
Cash From Financing Activities -230.0K -110.0K 11.91M
Net Change In Cash -6.050M -5.530M 6.370M
YoY Change -194.98% 48.66% -254.24%
FREE CASH FLOW
Cash From Operating Activities -$5.610M -$5.420M -$5.460M
Capital Expenditures -$210.0K $0.00 -$80.00K
Free Cash Flow -$5.400M -$5.420M -$5.380M
YoY Change 0.37% 0.18% 21.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Shell Company
EntityShellCompany
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q3 us-gaap Cash
Cash
6539444
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2861659
CY2019Q3 us-gaap Inventory Net
InventoryNet
687186
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
497121
CY2019Q3 us-gaap Assets Current
AssetsCurrent
10585410
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1325255
CY2019Q3 bioc Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
2610249
CY2018Q3 bioc Shares Available For Public Offering
SharesAvailableForPublicOffering
642438
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
8938408
CY2019Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
4748
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1793720
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1700380
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3179612
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
7158996
us-gaap Costs And Expenses
CostsAndExpenses
20711347
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6007983
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
2832735
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1163546
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1089746
us-gaap Cost Of Revenue
CostOfRevenue
7616473
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
1296034
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5441354
CY2018Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1404192
CY2018Q4 us-gaap Assets
Assets
8750303
CY2019Q3 us-gaap Assets
Assets
14520914
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2039718
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1834020
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1928393
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1846984
CY2019Q3 bioc Supplier Financings
SupplierFinancings
132924
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
641536
CY2019Q3 bioc Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
1969285
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4609647
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5783213
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
985015
CY2019Q3 bioc Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
1032243
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
113122
CY2018Q4 us-gaap Liabilities
Liabilities
5707784
CY2019Q3 us-gaap Liabilities
Liabilities
6815456
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
463
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
2302
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
223499634
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
247685038
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220457578
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239981882
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3042519
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
7705458
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8750303
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14520914
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4417
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2133
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4417
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2133
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4629174
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23018235
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4629174
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23018235
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
761591
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1529262
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2390772
CY2018Q3 us-gaap Cost Of Revenue
CostOfRevenue
2481916
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1462335
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4473908
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
6769574
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5629734
us-gaap Operating Income Loss
OperatingIncomeLoss
-18320575
CY2018Q3 us-gaap Interest Expense
InterestExpense
63764
CY2019Q3 us-gaap Interest Expense
InterestExpense
62028
us-gaap Interest Expense
InterestExpense
230677
CY2018Q3 bioc Warrant Inducement And Other Income Expenses
WarrantInducementAndOtherIncomeExpenses
23963
bioc Warrant Inducement And Other Income Expenses
WarrantInducementAndOtherIncomeExpenses
-6037
bioc Warrant Inducement And Other Income Expenses
WarrantInducementAndOtherIncomeExpenses
-1831116
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-39801
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-62028
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6047784
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5691762
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
13099551
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
297669
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
739
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-6047784
CY2018Q3 bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
636370
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
225263
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
8506975
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
173694
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-6153101
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
113072
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
102459
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5916787
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
14014084
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
224641
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
4845722
CY2019Q2 bioc Adjustment To Additional Paid In Capital Warrant Inducement Expense
AdjustmentToAdditionalPaidInCapitalWarrantInducementExpense
1831116
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7816012
us-gaap Depreciation And Amortization
DepreciationAndAmortization
580366
us-gaap Depreciation And Amortization
DepreciationAndAmortization
691191
bioc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
-113419
bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
92488
bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
-20277
us-gaap Share Based Compensation
ShareBasedCompensation
512029
us-gaap Share Based Compensation
ShareBasedCompensation
624769
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
1831116
us-gaap Paid In Kind Interest
PaidInKindInterest
29425
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
283028
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1287334
CY2018Q1 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
8.82
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-9692
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
120241
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-277720
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-322299
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
413562
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-198400
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
497119
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
76932
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-241034
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-82329
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16936994
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17577368
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
145253
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
297877
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-145253
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-297877
bioc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
25688205
bioc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
16779772
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2513172
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2337298
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
160111
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
378389
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
438290
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
260537
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1197968
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23891836
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20991316
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6809589
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3116071
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2146611
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3423373
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8956200
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6539444
us-gaap Interest Paid Net
InterestPaidNet
379587
us-gaap Interest Paid Net
InterestPaidNet
187574
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
739
bioc Financial Guarantee Insurance Contracts Cancelled Premium Remaining Principal Outstanding
FinancialGuaranteeInsuranceContractsCancelledPremiumRemainingPrincipalOutstanding
31000
bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
488000
bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
393000
bioc New Financial Guarantee Insurance Contracts Premium Payable
NewFinancialGuaranteeInsuranceContractsPremiumPayable
80000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
270000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
583000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
31000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
55000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
25000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
67000
CY2018Q1 bioc Class Of Warrant Or Rights Term
ClassOfWarrantOrRightsTerm
P5Y
CY2018Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
9700000
CY2018Q1 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
1400000
CY2018Q3 bioc Aggregate Number Of Units Sold Pursuant To Right Offering
AggregateNumberOfUnitsSoldPursuantToRightOffering
11587
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2018Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11600000
CY2018Q3 bioc Class Of Warrant Or Rights Term
ClassOfWarrantOrRightsTerm
P5Y
CY2018Q3 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
8400000
CY2018Q3 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
1400000
CY2018Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1012622
CY2019Q3 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
36
CY2018Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2500000
CY2018Q3 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
2000000
CY2018Q3 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
300000
CY2018Q3 bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
636000
CY2019Q1 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
2000000
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.20
CY2018Q1 bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
99000
CY2019Q1 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
7500000
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5950000
CY2019Q1 us-gaap Share Price
SharePrice
1.37
CY2019Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.25
CY2019Q1 bioc Class Of Warrant Or Rights Term
ClassOfWarrantOrRightsTerm
P5Y6M
CY2019Q2 bioc Class Of Warrant Or Right Number Of Warrant Exercised
ClassOfWarrantOrRightNumberOfWarrantExercised
4100000
CY2019Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4800000
CY2018Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.03
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On July 6, 2018, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s Certificate of Amendment of Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Company’s outstanding common stock.
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-24600000
CY2019Q3 bioc Aggregate Net Interest Bearing Indebtedness
AggregateNetInterestBearingIndebtedness
1900000
CY2019Q3 bioc Aggregate Net Interest Bearing Indebtedness Due Within One Year
AggregateNetInterestBearingIndebtednessDueWithinOneYear
909000
CY2019Q3 bioc Other Non Interest Bearing Current Liabilities
OtherNonInterestBearingCurrentLiabilities
3000000
CY2016Q1 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
1062500
bioc Unconditional Purchase Commitment Frequency Of Periodic Payment
UnconditionalPurchaseCommitmentFrequencyOfPeriodicPayment
Quarterly
us-gaap Unrecorded Unconditional Purchase Obligation Date
UnrecordedUnconditionalPurchaseObligationDate
2020-05-31
CY2019Q3 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
154000
CY2018Q3 bioc Proceeds From Issuance Of Units Net Of Issuance Expenses Related To Rights Offering
ProceedsFromIssuanceOfUnitsNetOfIssuanceExpensesRelatedToRightsOffering
10100000
CY2018Q3 bioc Proceeds From Issuance Of Units Net Of Issuance Expenses Related To Rights Offering
ProceedsFromIssuanceOfUnitsNetOfIssuanceExpensesRelatedToRightsOffering
2200000
CY2018Q3 bioc Conversion Of Preferred Stock To Common Stock Conversion Price
ConversionOfPreferredStockToCommonStockConversionPrice
4.53
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.20
CY2019Q3 bioc Warrant Inducement Expense
WarrantInducementExpense
1800000
bioc Warrant Inducement Expense
WarrantInducementExpense
1800000
CY2018Q3 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
3.30
CY2018Q3 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
2.57
CY2019Q1 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
0.95
CY2019Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
6800000
CY2019Q1 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
1.01
CY2019Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
6000000
CY2019Q2 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
1.18
CY2019Q2 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
1800000
CY2018Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2818583
CY2019Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2845053
CY2018Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
157391
CY2019Q3 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
156987
CY2018Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
1437408
CY2019Q3 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
1552981
CY2018Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
570173
CY2019Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
570174
CY2018Q4 bioc Finance Leased Assets Gross
FinanceLeasedAssetsGross
2573955
CY2018Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
116640
CY2019Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
325550
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7674150
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5450745
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4934728
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4125490
CY2018Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
255426
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1035210
CY2019Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1575039
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1193255
CY2019Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
776030
CY2019Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
636167
CY2018Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
62767
CY2019Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
81101
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
158342
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
203602
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
104155
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
us-gaap Depreciation
Depreciation
691191
CY2019Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
458750
CY2018Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
535682
CY2019Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
566811
CY2018Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
712574
us-gaap Depreciation
Depreciation
580366
CY2019Q3 us-gaap Depreciation
Depreciation
240207
CY2018Q3 us-gaap Depreciation
Depreciation
223194
CY2019Q1 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
149000
CY2019Q1 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q1 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
36
CY2019Q1 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
5013
CY2019Q1 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
180000
CY2019Q1 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2022-02
CY2019Q3 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
100000
CY2019Q3 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q3 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
48
CY2019Q3 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
2706
CY2019Q3 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
130000
CY2019Q3 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2023-05
CY2019Q3 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
245000
CY2019Q3 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q3 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
8253
CY2019Q3 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
297000
CY2019Q3 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2022-08
CY2019Q3 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
89000
CY2019Q3 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q3 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
60
CY2019Q3 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
1770
CY2019Q3 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
106000
CY2019Q3 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2024-09
CY2019Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1032243
CY2019Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
134472
CY2019Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
62026
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
187574
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
318005
us-gaap Operating Lease Cost
OperatingLeaseCost
954015
CY2019Q3 bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
514503
bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
1505990
CY2019Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
222245
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
764533
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
517927
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
405318
CY2019Q3 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
263274
CY2019Q3 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
58448
CY2019Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2231745
CY2019Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
423472
CY2019Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1808273
CY2019Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Remainder Of Fiscal Year
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsRemainderOfFiscalYear
27016
CY2019Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Two Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInTwoYears
89136
CY2019Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Three Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInThreeYears
67974
CY2019Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Four Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInFourYears
57260
CY2019Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Five Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInFiveYears
56799
CY2019Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due Thereafter
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueThereafter
8241
CY2019Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDue
306426
CY2019Q3 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Net
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsNet
306426
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
362929
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
855136
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1218065
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
24810
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1193255
CY2019Q3 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
62026
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
187574
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
355813
us-gaap Operating Lease Payments
OperatingLeasePayments
1067437
CY2019Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
101139
CY2019Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M8D
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10M2D
CY2019Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.2030
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.045
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
583000
bioc Share Based Compensation Arrangement By Share Based Payment Award Number Of Equity Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEquityIncentivePlans
2
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
195820
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2664129
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
62293
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2797656
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2701017
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
41.41
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.91
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.43
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.62
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.71
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M7D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y6M7D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
CY2019Q3 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
0
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7490672
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18466658
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7490672
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18466658
CY2018Q3 bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
25000
CY2019Q3 bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
35000
bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
75000
bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
82000

Files In Submission

Name View Source Status
0001564590-19-043276-index-headers.html Edgar Link pending
0001564590-19-043276-index.html Edgar Link pending
0001564590-19-043276.txt Edgar Link pending
0001564590-19-043276-xbrl.zip Edgar Link pending
bioc-10q_20190930.htm Edgar Link pending
bioc-20190930.xml Edgar Link completed
bioc-20190930.xsd Edgar Link pending
bioc-20190930_cal.xml Edgar Link unprocessable
bioc-20190930_def.xml Edgar Link unprocessable
bioc-20190930_lab.xml Edgar Link unprocessable
bioc-20190930_pre.xml Edgar Link unprocessable
bioc-ex311_6.htm Edgar Link pending
bioc-ex312_9.htm Edgar Link pending
bioc-ex321_8.htm Edgar Link pending
bioc-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending